KATHERINE RUTHERFORD: Open Payments
NPI 1396347738 · WINCHESTER, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$647 in 26 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $394 · 2025 $647
Food & beverage: $597Education: $51
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $149 |
| Novartis Pharmaceuticals Corporation | 6 | $127 |
| AstraZeneca Pharmaceuticals LP | 2 | $60 |
| Mallinckrodt Hospital Products Inc. | 2 | $56 |
| Calliditas Therapeutics US Inc. | 2 | $50 |
| Otsuka America Pharmaceutical, Inc. | 2 | $49 |
| Ardelyx, Inc. | 1 | $33 |
| GlaxoSmithKline, LLC. | 1 | $25 |
| Aurinia Pharma U.S., Inc. | 1 | $24 |
| Travere Therapeutics, Inc. | 1 | $23 |
Products named: Kerendia, Fabhalta, FARXIGA, TARPEYO, JARDIANCE, ACTHAR, IBSRELA, JYNARQUE.
Industry payments across VA — which companies pay providers there.
